BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 34479794)

  • 21. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
    Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
    Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
    Landgren O; Kyle RA; Pfeiffer RM; Katzmann JA; Caporaso NE; Hayes RB; Dispenzieri A; Kumar S; Clark RJ; Baris D; Hoover R; Rajkumar SV
    Blood; 2009 May; 113(22):5412-7. PubMed ID: 19179464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
    N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
    El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
    Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.
    Weiss BM; Kuehl WM
    Expert Rev Hematol; 2010 Apr; 3(2):165-74. PubMed ID: 20473362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
    Zingone A; Kuehl WM
    Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
    Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
    Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
    Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
    Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal gammopathy of uncertain significance (MGUS) and ionizing radiation].
    Taino G; Buonocore C; Stanga A; Imbriani M
    G Ital Med Lav Ergon; 2020 Dec; 42(4):292-297. PubMed ID: 33600657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study.
    Gupta R; Dahiya M; Kumar L; Shekhar V; Sharma A; Ramakrishnan L; Sharma OD; Begum A
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e345-e350. PubMed ID: 29980412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.
    Vachon CM; Kyle RA; Therneau TM; Foreman BJ; Larson DR; Colby CL; Phelps TK; Dispenzieri A; Kumar SK; Katzmann JA; Rajkumar SV
    Blood; 2009 Jul; 114(4):785-90. PubMed ID: 19179466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Landgren O; Hofmann JN; McShane CM; Santo L; Hultcrantz M; Korde N; Mailankody S; Kazandjian D; Murata K; Thoren K; Ramanathan L; Dogan A; Rustad E; Lu SX; Akhlaghi T; Kristinsson SY; Björkholm M; Devlin S; Purdue MP; Pfeiffer RM; Turesson I
    JAMA Oncol; 2019 Sep; 5(9):1293-1301. PubMed ID: 31318385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.
    Weiss BM; Minter A; Abadie J; Howard R; Ascencao J; Schechter GP; Kuehl M; Landgren O
    Am J Hematol; 2011 Jun; 86(6):475-8. PubMed ID: 21544856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.